Suppr超能文献

采用横断面成像评估接受新辅助全身治疗的乳腺癌患者区域淋巴结疾病的范围。

Cross-sectional imaging to evaluate the extent of regional nodal disease in breast cancer patients undergoing neoadjuvant systemic therapy.

作者信息

Anderson Tara L, Glazebrook Katrina N, Murphy Brittany L, Viers Lyndsay D, Hieken Tina J

机构信息

Mayo Clinic, Department of Radiology, 200 First Street SW, Rochester, MN, 55905, USA.

Mayo Clinic, Department of Surgery, 200 First Street SW, Rochester, MN, 55905, USA.

出版信息

Eur J Radiol. 2017 Apr;89:163-168. doi: 10.1016/j.ejrad.2017.01.030. Epub 2017 Feb 7.

Abstract

PURPOSE

Cross-sectional imaging often is performed in breast cancer patients undergoing neoadjuvant systemic therapy (NST) and may identify level III axillary and extra-axillary nodal disease. Our aim was to investigate associations of radiologic nodal staging with pathological N (pN) stage at operation and to explore how this might aid surgical and radiotherapy treatment planning.

MATERIALS AND METHODS

With IRB approval, we reviewed pre-treatment breast MRI, PET/CT, and CT imaging and clinicopathologic data on 348 breast cancer patients with imaging available for review undergoing NST followed by operation at our institution 1/2008-9/2013. We defined abnormal lymph node findings on MRI, CT, and PET/CT to include cortical thickening, FDG-avidity and loss of fatty hilum. Patients were assigned a radiologic nodal (rN) stage based on imaging findings. Statistical analysis was performed using JMP 10.1 software RESULTS: Pre-NST imaging included axillary ultrasound in 338 patients (97%), breast MRI in 305 (88%) and PET/CT or CT in 215 (62%). 213 patients (61%) were biopsy-proven axillary lymph node-positive (LN+) pre-treatment. cT stage was T1 in 9%, T2 in 49%, T3 in 29%, T4 in 12%; median tumor size was 4cm. Pre-treatment rN stage across all the patients was rN0 in 86 (25%), rN1 in 173 (50%), and rN3 in 89 (26%). rN3 disease included level III axillary, supraclavicular and suspicious internal mammary lymph nodes in 47 (53%), 32 (37%) and 45 (52%), respectively. Of patients LN+ at diagnosis, 78 (37%) were rN3. After NST, 162 patients (47%) were node-positive at operation with a median (mean) of 3 (5.9±0.4) positive lymph nodes including 128 of 213 (60%) LN+ at diagnosis. Pre-NST rN stage correlated with the likelihood and extent of axillary disease at operation, p=0.002. Fifty four of 89 rN3 patients (61%) were node-positive at operation with a median (mean) of 5 (8±1) positive nodes. rN3 patients had larger nodal metastases (median 9 vs 6mm) and more frequent extranodal extension (61% vs 43%) than rN0/rN1 patients, both p<0.03.

CONCLUSIONS

Information on rN stage from pre-NST cross-sectional imaging informs the likelihood and extent of axillary nodal disease at operation. This information may be used for surgical and radiotherapy treatment planning and to inform patient expectations.

摘要

目的

横断面成像常用于接受新辅助全身治疗(NST)的乳腺癌患者,可能会发现Ⅲ级腋窝及腋窝外淋巴结疾病。我们的目的是研究放射学淋巴结分期与手术时病理N(pN)分期之间的关联,并探讨这如何有助于手术和放射治疗计划的制定。

材料与方法

经机构审查委员会(IRB)批准,我们回顾了2008年1月至2013年9月在我院接受NST并随后接受手术的348例乳腺癌患者的治疗前乳腺MRI、PET/CT和CT成像以及临床病理数据,这些患者的成像资料可供审查。我们将MRI、CT和PET/CT上异常淋巴结表现定义为包括皮质增厚、FDG摄取及脂肪门消失。根据成像结果为患者指定放射学淋巴结(rN)分期。使用JMP 10.1软件进行统计分析。结果:NST前成像包括338例患者(97%)进行了腋窝超声检查,305例(88%)进行了乳腺MRI检查,215例(62%)进行了PET/CT或CT检查。213例患者(61%)在治疗前经活检证实腋窝淋巴结阳性(LN+)。cT分期为T1期的占9%,T2期的占49%,T3期的占29%,T4期的占12%;肿瘤中位大小为4cm。所有患者治疗前rN分期为rN0的有86例(25%),rN1的有173例(50%),rN3的有89例(26%)。rN3疾病分别包括Ⅲ级腋窝、锁骨上及可疑内乳淋巴结,分别为47例(53%)、32例(37%)和45例(52%)。诊断时LN+的患者中,78例(37%)为rN3。NST后,162例患者(47%)手术时淋巴结阳性,阳性淋巴结中位数(平均数)为3个(5.9±0.4个),其中213例诊断时LN+的患者中有128例(60%)。治疗前rN分期与手术时腋窝疾病的可能性及范围相关,p = 0.002。89例rN3患者中有54例(61%)手术时淋巴结阳性,阳性淋巴结中位数(平均数)为5个(8±1个)。rN3患者的淋巴结转移灶比rN0/rN1患者更大(中位值9 vs 6mm)且结外扩展更频繁(61% vs 43%),两者p均<0.03。

结论

治疗前横断面成像的rN分期信息可提示手术时腋窝淋巴结疾病的可能性及范围。该信息可用于手术和放射治疗计划的制定,并告知患者预期情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验